Genome instability and success of checkpoint inhibitors: form and levels matter

S Derks¹

Affiliations

¹ Amsterdam UMC, Location VUmc, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands. Electronic address: s.derks@amsterdamumc.nl.

Free article

Editorial

S Derks. Ann Oncol. 2021 Sep.

Free article

. 2021 Sep;32(9):1073-1074.

doi: 10.1016/j.annonc.2021.06.022. Epub 2021 Jun 30.

S Derks¹

¹ Amsterdam UMC, Location VUmc, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands. Electronic address: s.derks@amsterdamumc.nl.

No abstract available

Conflict of interest statement

Disclosure The author has declared no conflicts of interest.

Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma.
Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Caglevic C, Chung HC, Muro K, Van Cutsem E, Kobie J, Cristescu R, Aurora-Garg D, Lu J, Shih CS, Adelberg D, Cao ZA, Fuchs CS. Shitara K, et al. Ann Oncol. 2021 Sep;32(9):1127-1136. doi: 10.1016/j.annonc.2021.05.803. Epub 2021 May 31. Ann Oncol. 2021. PMID: 34082019 Clinical Trial.